Most recently, he served as VP Global Site Network at Accelerated Enrollment Solutions, a business of PPD, which is a leading global contract research organization. In this role, he had oversight of more than 160 clinical research sites and 1,300 full-time employees in 15 countries. Prior to this, as VP at PPD, he served as the Head of Early Development clinical research sites. Before joining PPD, he spent 17 years at Parexel in various roles supporting the company’s clinical research site strategy.

In addition to holding an MBA, Reinhold holds degrees in Pharmacology, Physiology, Chemistry, and Biochemistry.

“From my university days majoring in Pharmacology and the Sciences through present day, I have always been passionate about drug development and clinical research. I learned about drug development from the ground up and value excellence in every aspect of the process. For me, leading with science and solving problems for our clients have always been at the forefront. I am proud that these are the principles embedded in the Flourish Research culture.”

The post Reinhold Schulz appeared first on Flourish Research.

Before joining Flourish, Anthony served as CFO at BioCryst Pharmaceuticals (Nasdaq: BCRX), where he led the company through a transformational growth phase—from a clinical stage biotech to a global rare disease leader with almost $500M in revenue and a $2B+ market cap. During his tenure, BioCryst raised over $1B in capital and achieved operational profitability and capital market independence. 

Prior to those roles, he held a broad array of financial positions of increasing responsibility at Worldwide Clinical Trials, World Book (A Berkshire Hathaway company), and General Electric where he graduated from their acclaimed Financial Management and Corporate Audit Staff Programs.  

Named one of the Top 25 Biotech CFOs of 2024, Anthony is passionate about unlocking business potential through data insights and data-driven decision-making, while empowering teams to achieve extraordinary success, and is privileged to do this in an industry focused on improving patient outcomes. 

The post Anthony Doyle appeared first on Flourish Research.

Most recently, he served as Chief Operating and Development Officer for Acorn Health, one the country’s largest clinical providers of applied behavioral analysis therapy given to children diagnosed with autism spectrum disorder. In this role, he led the growth and oversight of 70 treatment centers across the country.  Additionally, he serves on the Board of Directors of Inner Haven Wellness, a leading clinic-based eating disorder treatment provider in the US.   Prior to this, he served as the Chief Financial Officer of Costa Farms, North America’s largest manufacturer and distributor of ornamental plants.

Jose began his career in the audit practice of Ernst & Young, one of the country’s largest professional services firms. Jose holds a Bachelor of Science in Accounting and Finance from the University of Miami.

“High growth companies can lead to all sorts of new and complex opportunities… being able to navigate through these complexities requires an authentic “people first” approach.  As a servant leader, I aspire to help our team engage in a collaborative, open and empowered network.  Flourish Research has experienced exceptional growth and I am proud that it has done so by fostering the human element.”

The post Jose Alvarez appeared first on Flourish Research.

As President of Biopharma at Emmes, she led strategic expansions and M&A initiatives, resulting in five acquisitions in 2.5 years. Previously, at PPD, she built global teams, enhanced patient access to clinical trials, and forged key industry partnerships. Passionate about advancing diversity in clinical research, Rhonda brings a results-driven approach to leadership. She holds a BSN from the University of North Carolina Wilmington and has been recognized as one of PharmaVoice’s 100 Most Inspiring Patient Champions.

The post Rhonda Henry appeared first on Flourish Research.

He has successfully led multidisciplinary teams in Pharma, Biotech, Clinical Research Organizations (CROs), and clinical research site networks—consistently building high-performing commercial functions that accelerate revenue and expand market presence. Known for bridging scientific innovation with business acumen, David excels at identifying and capturing new market opportunities, forging strategic partnerships, and aligning organizational capabilities to meet evolving industry demands.

With deep expertise in the life sciences value chain and a track record of scaling organizations in competitive markets, David combines visionary leadership with executional precision to drive sustainable growth.

The post David Watkins appeared first on Flourish Research.

Most recently, she headed the Global Site Network at Accelerated Enrollment Solutions (AES), a business of PPD, a leading global research organization. In this role, she directed over 45 sites in the US and LATAM. Prior to this, she served as the Head of Business Information at AES, leading the site network business strategy initiatives, global site standards, and process optimization. Before joining AES, Brooke spent 19 years at Parexel in a wide range of roles supporting the company’s research site strategy and global project management.

A Registered Nurse, Brooke holds a Bachelor of Science in both Biology and Nursing, and a Master of Science in Clinical Research Management and Organization.

“I am passionate about creating and implementing systems to ensure that Flourish Research leads the industry in quality. It gives me tremendous gratification to see our employees grow and develop, upholding our company’s exceptionally high standard for integrity, ethics, and quality.”

The post Brooke Evans appeared first on Flourish Research.

At Flourish Research, he is responsible for legal, compliance, and human resources operations. Geoff focuses on creating strong partnerships across the organization to accelerate innovation, manage risk and compliance, and enable sustainable business growth.

Before joining Flourish, Geoff served as Chief Administrative Officer and General Counsel at Agile Therapeutics, guiding the company from IPO through FDA approval, commercialization, and acquisition. He previously served as Senior Vice President and General Counsel at Amicus Therapeutics, held senior leadership roles at Bristol-Myers Squibb, and has advised numerous emerging biotech and pharmaceutical organizations on clinical, regulatory, and commercial readiness strategies.

Driven by a lifelong passion for drug development, Geoff works to bridge science, strategy, and execution to help accelerate high-quality clinical research and the delivery of new therapies.

Geoff holds a J.D. from the University of Michigan Law School and an A.B. with honors in Classics from Franklin & Marshall College.

The post Geoff Gilmore appeared first on Flourish Research.

He is a Master of the American Society for Preventive Cardiology and holds fellowships with numerous organizations, including the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, and the National Lipid Association.

With two books and over 150 peer-reviewed papers and abstracts, Dr. Baum has been published in leading journals such as Nature, The Journal of the American College of Cardiology, Circulation, The New England Journal of Medicine, and The Lancet.

Since 2000, his primary focus has been on Preventive Cardiology and Clinical Lipidology. In 2005, he was among the first group to become Board Certified by the American Board of Clinical Lipidology. Dr. Baum has held leadership roles at the American Society for Preventive Cardiology (ASPC) since 2010, eventually becoming its President in 2016. He has also been an active member of the Family Heart Foundation since 2015, serving on its Board of Directors and Scientific Advisory Board. In 2024, he was elected Chairman of the Family Heart Foundation’s Board of Directors.

Dr. Baum is deeply passionate about advancing research in cardiovascular and metabolic health, with a focus on improving patient outcomes and fostering innovation in the field. In recognition of his lifelong dedication to Preventive Medicine, he was awarded Cleveland Heart Lab’s “Heart Award” in 2013. In 2019, Mended Hearts honored him with the biennial Dwight Emary Harken Award.

In 2016, Dr. Baum founded Excel Medical Clinical Trials (EMCT), initially focusing on lipid and lipoprotein disorders. In 2021, EMCT was selected as one of two platform sites that founded Flourish Research. Since then, Flourish’s therapeutic focus has expanded to three areas, Cardiovascular/Metabolic/Renal, Neuroscience, and Infectious Disease. Since 2022, Dr. Baum has served as Flourish’s Chief Medical Officer, helping grow the organization into a leading site network that currently spans the United States.

“It has been a privilege to help thousands of patients during my nearly 40-year career in Medicine. Working in clinical research, however, has enabled me to dramatically expand my reach. Participating in clinical trials, I have been fortunate to help bring life-saving medications to literally millions of people. Flourish Research fosters excellence in all aspects of the conduct of clinical trials and I am proud to be a part of the company.”

Contact us about your next trial at bd@flourishresearch.com.

The post Seth J. Baum appeared first on Flourish Research.

He received his medical degree cum laude at Harvard Medical School, and he completed residency in internal medicine and chief residency and fellowship in cardiology at New York Hospital/Memorial Sloan-Kettering Cancer Center/Cornell Medical Center. 

Dr. Koren is a fellow of the American College of Cardiology. He is a fellow and two-time past president of the Academy of Physicians in Clinical Research and past president of the regional chapter of the American Heart Association. As an ACRP Certified Principal Investigator, Dr. Koren has led more than 500 clinical trials on hypercholesterolemia, cardiovascular disease, and heart failure. He participates in the Cholesterol Treatment Trialist Collaboration based in Oxford. 

Dr. Koren’s research has been published in peer-reviewed journals including Nature, Journal of the American College of Cardiology, Circulation, New England Journal of Medicine, and The Lancet. He has lectured nationally and internationally on topics such as lipid-lowering therapy and preventive cardiology. 

Currently, he oversees active protocols developing mRNA vaccines and early-phase research in preventative cardiology. 

Contact us about your next trial at bd@flourishresearch.com.

The post Michael J. Koren appeared first on Flourish Research.

Ophelia is a results-focused leader who has helped companies channel the full potential of their most valuable assets – their people.

Ophelia holds a Bachelor of Business Management and a Master of Business Administration (Global Management Concentration) from the University of Phoenix. She is a certified mediator and holds Advanced Consulting and Crucial Conversation certificates.

“My greatest accomplishment is the contribution made to inspiring corporate culture change that cultivates business growth, while keeping the human factor at the forefront. I am thrilled to lead the HR team at Flourish Research, a progressive, people-centric company that genuinely always aims to ‘do the right thing.’”

The post Ophelia Hill appeared first on Flourish Research.